Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Participant was \>8 months of age at the time of dosing.~2. Confirmation of LAL-D diagnosis as determined by the central laboratory or, for participants with prior hematopoietic stem cell transplant or liver transplant, historical enzyme activity or molecular genetic testing confirming a diagnosis of LAL-D.~3. Participants \>8 months but \<4 years of age at Screening had at least 1 of the following documented clinical manifestations of LAL-D:~   * Dyslipidemia~  * Elevated transaminases~  * Impaired growth~  * Suspected malabsorption~  * Other clinical manifestation of LAL-D~4. Participants ≥4 years of age at Screening had at least 1 of the following documented clinical manifestations of LAL-D:~   * Evidence of advanced liver disease~  * Histologically confirmed disease recurrence in participants with past liver or hematopoietic transplant~  * Persistent dyslipidemia~  * Suspected malabsorption~  * Other clinical manifestation of LAL-D~Key Exclusion Criteria:~1. Participant had known causes of active liver disease other than LAL-D, which had not been adequately treated.~2. Participant received a hematopoietic stem cell or liver transplant \<2 years from the time of dosing.~3. Participant with co-morbidities other than complications due to LAL-D, which were irreversible or associated with a high mortality risk within 6 months or would interfere with study compliance or data interpretation.

- Gender: ALL
- Minimum Age: 8 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sebelipase Alfa (Type: EXPERIMENTAL): Pediatric and adult participants initiated IV treatment with sebelipase alfa at a dose of 1 mg/kg qow. Participants were considered for a dose adjustment at the discretion of the Investigator and in consultation with the Sponsor. Dose escalation to 3 mg/kg qow was considered if pre-defined dose-escalation criteria were met. If these criteria continued to be met, a subsequent dose escalation to 3 mg/kg every week (qw) was considered. Dose decreases as low as 0.35 mg/kg qow were permitted based upon evidence of intolerance to sebelipase alfa treatment. Participants who completed the 96-week treatment period were permitted to continue receiving sebelipase alfa in an expanded treatment period for up to 48 weeks, pending local drug availability and study participation status.

Based on this trial design, predict the completion outcome and termination type (if applicable).